EktaH Advances NKS-3 into Phase 2 Trials for Obesity Treatment
EktaH has enrolled the first patient in its Phase 2a SERENITY-1 study evaluating oral candidate NKS-3 for obesity treatment in Tunisia.
Placebo-controlled Trial | 17/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy